Nasal Immunotherapy Shows Promise in Reducing Inflammation and Boosting Cognitive Function in Alzheimer's Disease

▴ Alzheimer's Disease
The discovery of nasal immunotherapy with anti-CD3 as a potential treatment for Alzheimer's disease represents a ray of hope for the millions of individuals and their families affected by this devastating condition.

Alzheimer's disease is a devastating condition characterized by neurodegeneration and inflammation in the brain. Finding effective treatments for this complex disease has been challenging, as most existing therapies focus on targeting amyloid beta plaques and require early intervention through intravenous therapy. However, recent research has unveiled a promising new approach - nasal immunotherapy with anti-CD3 - which has shown potential in reducing inflammation and enhancing cognitive function in Alzheimer's disease.

The Breakthrough:

In a groundbreaking study published in the journal PNAS, researchers have uncovered preclinical evidence suggesting that nasal immunotherapy can offer significant benefits to individuals battling Alzheimer's disease. What sets this therapy apart is its ability to reduce inflammation and improve cognition independently of amyloid beta plaque levels.

Anti-CD3 Nasal Immunotherapy:

The novel nasal immunotherapy, referred to as anti-CD3, has shown remarkable results in Alzheimer's mouse models. The treatment involves administering anti-CD3 intranasally three times a week for five months. During this time, researchers observed a notable decrease in the activation of microglia, which are immune cells responsible for inflammation in the brain.

Improved Cognitive Function:

The positive effects of anti-CD3 immunotherapy were not limited to reduced inflammation. Treated mice exhibited enhanced cognitive function as demonstrated by improved performance in various behavioral tests, including a water maze. These improvements in cognition are a significant breakthrough, as cognitive decline is a hallmark of Alzheimer's disease.

Immune System Response:

The study also unveiled intriguing changes in gene expression patterns within the brain and an expansion of regulatory T cells, which play a crucial role in fighting diseases in the body. Importantly, all of these changes occurred independently of amyloid beta plaque levels, suggesting that this therapy targets aspects of Alzheimer's disease that have previously been challenging to address.

Promising Implications:

Corresponding author Howard L. Weiner from the Department of Neurology at Brigham and Women's Hospital in the US expressed "We provide evidence that intranasal anti-CD3 therapy can dampen microglia activation and expand T cells in a murine model of Alzheimer’s. This represents a unique approach to treating later-stage Alzheimer’s that can be applied to other inflammatory disease conditions as well."

Future Prospects:

Researchers are now planning to further investigate the potential of anti-CD3 immunotherapy in combination with anti-amyloid therapies in animal studies. This step is crucial in understanding how these treatments can work together to provide a comprehensive approach to Alzheimer's disease treatment. Ultimately, the goal is to advance this promising therapy into human clinical trials.

Building on Success:

This exciting breakthrough builds upon previous research by the same team, who explored the use of foralumab, the only fully human anti-CD3 monoclonal antibody treatment, in patients with COVID-19 and multiple sclerosis (MS). These efforts underscore the versatility of anti-CD3 immunotherapy in addressing a range of inflammatory conditions.


The discovery of nasal immunotherapy with anti-CD3 as a potential treatment for Alzheimer's disease represents a ray of hope for the millions of individuals and their families affected by this devastating condition. As researchers continue to explore this innovative approach, there is optimism that it may offer a unique and effective way to combat Alzheimer's disease, while also holding promise for other inflammatory diseases. Further studies and clinical trials will shed more light on the full potential of this therapy in the fight against Alzheimer's

Tags : #alzheimer #nasal #immunotherapy #brainhealth #inflammatorydiseases #anti-CD3 #COVID19 #medicircle

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

NephroPlus to Launch Nationwide Free Health Screening Campaign to Commemorate World Kidney Day 2025 March 07, 2025
Skinny But Sick? Is our Body Mass Index Misleading UsMarch 07, 2025
Scientists Stumble Upon a Cancer-Fighting Secret Hidden in Your Medicine CabinetMarch 07, 2025
The Bitter Truth About Butter: Is our Favourite Spread Cutting our Life Short?March 07, 2025
March 07, 2025
March 06, 2025
University of Leeds scientists offer hope for people facing chronic painMarch 06, 2025
Impact of excessive use of gym supplements on gym enthusiastsMarch 06, 2025
Himalaya Wellness Launches the Himalaya 1derwoman Project, Inspiring Young Girls to Be #1March 06, 2025
Gujarat’s Medical Education Expansion: A Game Changer or Just Numbers on Paper?March 06, 2025
440 Million at Risk: Is India Becoming the Next Obesity Capital?March 06, 2025
Mystery Illness Claims Lives in Chhattisgarh: Is It a Health Crisis in the Making?March 06, 2025
Rising obesity rate in kidsMarch 05, 2025
India’s Clinical Trials Market: Can We Leap from Underdog to Global Leader?March 05, 2025
India’s GBS Outbreak: Is Contaminated Water Fueling a Paralysis Crisis? March 05, 2025
3-Day-Old Baby Born with One Lung Gets a New Lease on Life at SRM Global Hospitals after Rare SurgeryMarch 04, 2025
3-Day-Old Baby Born with One Lung Gets a New Lease on Life at SRM Global Hospitals after Rare SurgeryMarch 04, 2025
Marico Unveils Game-Changing Innovation with the Launch of Saffola Cuppa Oats– A redefining moment in the Category!March 04, 2025
Growing Weight of India: Obesity burden tipping the scale, pushing a generation towards early mortalityMarch 04, 2025
Venus Remedies Secures Its First International Market Authorization for Sugammadex from the Philippines, Strengthening Presence in ASEAN’s High-Growth MarketMarch 04, 2025